News

Cancer stem cells caught
Enlarge image

ScienceBelgiumUK

Cancer stem cells caught

06.08.2012 - Belgian and UK researchers have for the first time tracked the existence of cancer stem cells in vivo. The study provides another piece of evidence that cancer stem cells are drivers of tumour recurrence.

The study published in Nature demonstrates for the first time the existence of cancer stem cells during unperturbed solid tumour growth. The team led by Cédric Blanpain from Université libre de Bruxelles found specific subsets of cells in mouse tumours that seem to be responsible for the re-growth of tumours. These findings shed new light on the controversial issue of whether cancer stem cells exist in growing tumours and may have implications for potential therapies.

Cancer stem cells are proposed to be responsible for tumour recurrence after anti-cancer treatments fail. However, evidence for cancer stem cells in solid tumours remained unproven so far. Blanpain and co-workers tracked tumour progression in mouse model of skin cancer and observe a persistent subpopulation of tumour cells with stem-like properties. There are two more groups publishing in parallel on their tracking success of cancer stem cells in Nature and Science.

http://www.european-biotechnology-news.com/news/news/2012-03/cancer-stem-cells-caught.html

PoliticsEU

15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.

BiosimilarsGermanyFrance

12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.

FinancingNetherlands

11.09.2014 Cystic fibrosis specialist Proqr Therapeutics has set the terms for its upcoming IPO at US-American stock exchange NASDAQ.

Clinical TrialsUKSweden

09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.

BusinessDenmark

04.09.2014 After their arthritis product’s Phase IIb failure, Novo Nordisk A/S is pulling out of all research and development activities within inflammatory disorders.

BusinessBelgiumIrelandSwitzerland

02.09.2014 In the face of declining revenue, Belgian biopharmaceutical company Thrombogenics has decided to spin out its cancer research and development activities.

ResearchUKSwitzerlandItaly

29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS0.09 CHF12.50%
  • PAION2.99 EUR11.15%
  • CO.DON3.00 EUR5.63%

FLOP

  • 4SC1.09 EUR-6.03%
  • STRATEC BIOMEDICAL39.80 EUR-3.40%
  • ADDEX3.22 CHF-3.30%

TOP

  • SANTHERA91.65 CHF43.0%
  • CO.DON3.00 EUR26.1%
  • PAION2.99 EUR20.1%

FLOP

  • EVOTEC3.07 EUR-18.1%
  • 4SC1.09 EUR-18.0%
  • MEDIGENE4.06 EUR-14.0%

TOP

  • SANTHERA91.65 CHF1987.7%
  • CO.DON3.00 EUR244.8%
  • PAION2.99 EUR187.5%

FLOP

  • CYTOS0.24 CHF-94.0%
  • 4SC1.09 EUR-43.2%
  • MERCK KGAA67.58 EUR-41.3%

No liability assumed, Date: 15.09.2014